..

COVID-19IIBR Updates You

The Israel Institute for Biological Research and NRx Pharmaceuticals have signed an MOU to complete clinical trials and commercialize “BriLife”

​NRx Pharmaceuticals, an international company traded on Nasdaq, will complete the clinical trials needed to increase the statistical sample and to prepare the necessary regulatory files in order to continue the clinical trials and conduct its third phase. The company will conduct clinical trials on tens of thousands of volunteers in the countries with which it has signed cooperation agreements. IIBR will accompany the process and will continue to share knowledge and provide scientific assistance to complete the clinical trials.

 

 

Our volunteers should receive a vaccination certificate

​Prof. Shmuel Shapira: “I understand, I sympathize and I'm doing my best to rectify the situation. It’s unfair to discriminate this honorable population. They deserve to receive this certificate.”​​

 

 

BriLife - Sharing information

Info​rmation regarding our vaccine’s clinical trials and list of medical centers taking part in the research​​

 

 

IIBR's Corona vaccine has been approved for phase two of the Clinical Trials

​Defense Minister, Benny Gantz: "The scientists of the IIBR are Israel's 'elite unit, and have taken on an extremely important task - saving human lives. I see great importance in the development of an Israeli vaccine that will continue to serve Israeli society for years to come."

 

 

Clinical trials for IIBR's vaccine will begin on Sunday, November 1st

​This is our vaccine's story from research to production

 

 

PHD

Women In Science

0

Fields of scientific knowledge

Biology

IIBR leads na​tional efforts to counter any and all biological threats from intentional attacks as well as naturally-emerging diseases. Using a multi-disciplinary project strategy, combined with cutting edge technologies, we develop methods for the identification of various bio-threats; forensic investigation of bio-terror agents and pathogenesis mech​anisms; design of new strategies for vaccine development, as well as evaluation of novel modalities of therapeutics. IIBR biotechnology cGMP multi-product facility, is designed for the development and production of bio-pharmaceuticals and unique vaccines for national preparedness. ​

EXPLORE
 

Environmental science

IIBR research and development concerning environmental sciences ranges from numerical mod​eling to laboratory and field​​​​ experiments in the areas of meteorology and atmospheric contaminants. IIBR has developed capabilities that enable detection and identification of hazardous materials, weather and dispersion prediction, physical protection and evaluation of potential risks.

EXPLORE
 

Chemistry

Toxicological eval​uation at IIBR is followed by the generation of novel treatment protocols and drugs, rapid and effective solutions for damage prevention and control. These are g​ained by a combination of cutting-edge synthetic capabilities and an advanced analytical toolbox. All are based on comprehensive pharmacological and pathophysiological understanding and advanced experimental means.​

EXPLORE
 
Collaborate

Newsroom

Scientific Publications

​IIBR's latest Scientific Publications in the fields of biology, chemistry and the environmental sciences​.

read moreaboutScientific Publications

News

​Read about IIBR in the press.





read moreaboutNews